Cargando…
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
BACKGROUND: Gemcitabine plus nab-paclitaxel (GA) and modified FOLFIRINOX (FFX) have been widely used as standard first-line treatment in pancreatic cancer. However, it is unclear which regimen is more efficacious. AIM: To evaluate a retrospective analysis comparing the efficacy and safety of FFX and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479547/ https://www.ncbi.nlm.nih.gov/pubmed/32953848 http://dx.doi.org/10.12998/wjcc.v8.i17.3718 |
_version_ | 1783580295695433728 |
---|---|
author | Han, Sung Yong Kim, Dong Uk Seol, Young Mi Kim, Suk Lee, Nam Kyung Hong, Seung Baek Seo, Hyung-Il |
author_facet | Han, Sung Yong Kim, Dong Uk Seol, Young Mi Kim, Suk Lee, Nam Kyung Hong, Seung Baek Seo, Hyung-Il |
author_sort | Han, Sung Yong |
collection | PubMed |
description | BACKGROUND: Gemcitabine plus nab-paclitaxel (GA) and modified FOLFIRINOX (FFX) have been widely used as standard first-line treatment in pancreatic cancer. However, it is unclear which regimen is more efficacious. AIM: To evaluate a retrospective analysis comparing the efficacy and safety of FFX and GA as first-line chemotherapeutic regimens in patients with metastatic pancreatic cancer. METHODS: We retrospectively analyzed and compared outcomes in 101 patients who presented with pancreatic cancer and were treated with either GA (n = 54) or FFX (n = 47). Moreover, we performed subgroup analysis based on the neutrophil/lymphocyte ratio (NLR) and Eastern Cooperative Oncology Group (ECOG) performance status. RESULTS: There were no significant differences between two groups in baseline characteristics, except for the ECOG performance status. The median progression-free survival (PFS) (6.43 mo vs 4.90 mo, P = 0.058) was comparable between two groups; however, median overall survival (OS) (10.17 mo vs 6.93 mo, P = 0.008) was longer in patients who received GA regimen. In patients with ECOG 0 (PFS: 8.93 mo vs 5.43 mo, P = 0.002; OS: 16.10 mo vs 6.97 mo, P = 0.000) and those with NLR < 3 (PFS: 8.10 mo vs 6.57 mo, P = 0.008; OS: 12.87 mo vs 9.93 mo, P = 0.002), GA regimen showed higher efficacy. CONCLUSION: GA regimen may be recommended to the patients with NLR < 3 or ECOG 0 status although GA and FFX showed comparable efficacy outcomes in patients with metastatic pancreatic cancer. |
format | Online Article Text |
id | pubmed-7479547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-74795472020-09-18 Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer Han, Sung Yong Kim, Dong Uk Seol, Young Mi Kim, Suk Lee, Nam Kyung Hong, Seung Baek Seo, Hyung-Il World J Clin Cases Retrospective Study BACKGROUND: Gemcitabine plus nab-paclitaxel (GA) and modified FOLFIRINOX (FFX) have been widely used as standard first-line treatment in pancreatic cancer. However, it is unclear which regimen is more efficacious. AIM: To evaluate a retrospective analysis comparing the efficacy and safety of FFX and GA as first-line chemotherapeutic regimens in patients with metastatic pancreatic cancer. METHODS: We retrospectively analyzed and compared outcomes in 101 patients who presented with pancreatic cancer and were treated with either GA (n = 54) or FFX (n = 47). Moreover, we performed subgroup analysis based on the neutrophil/lymphocyte ratio (NLR) and Eastern Cooperative Oncology Group (ECOG) performance status. RESULTS: There were no significant differences between two groups in baseline characteristics, except for the ECOG performance status. The median progression-free survival (PFS) (6.43 mo vs 4.90 mo, P = 0.058) was comparable between two groups; however, median overall survival (OS) (10.17 mo vs 6.93 mo, P = 0.008) was longer in patients who received GA regimen. In patients with ECOG 0 (PFS: 8.93 mo vs 5.43 mo, P = 0.002; OS: 16.10 mo vs 6.97 mo, P = 0.000) and those with NLR < 3 (PFS: 8.10 mo vs 6.57 mo, P = 0.008; OS: 12.87 mo vs 9.93 mo, P = 0.002), GA regimen showed higher efficacy. CONCLUSION: GA regimen may be recommended to the patients with NLR < 3 or ECOG 0 status although GA and FFX showed comparable efficacy outcomes in patients with metastatic pancreatic cancer. Baishideng Publishing Group Inc 2020-09-06 2020-09-06 /pmc/articles/PMC7479547/ /pubmed/32953848 http://dx.doi.org/10.12998/wjcc.v8.i17.3718 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Study Han, Sung Yong Kim, Dong Uk Seol, Young Mi Kim, Suk Lee, Nam Kyung Hong, Seung Baek Seo, Hyung-Il Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer |
title | Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer |
title_full | Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer |
title_fullStr | Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer |
title_full_unstemmed | Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer |
title_short | Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer |
title_sort | comparison of gemcitabine plus nab-paclitaxel and folfirinox in metastatic pancreatic cancer |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479547/ https://www.ncbi.nlm.nih.gov/pubmed/32953848 http://dx.doi.org/10.12998/wjcc.v8.i17.3718 |
work_keys_str_mv | AT hansungyong comparisonofgemcitabineplusnabpaclitaxelandfolfirinoxinmetastaticpancreaticcancer AT kimdonguk comparisonofgemcitabineplusnabpaclitaxelandfolfirinoxinmetastaticpancreaticcancer AT seolyoungmi comparisonofgemcitabineplusnabpaclitaxelandfolfirinoxinmetastaticpancreaticcancer AT kimsuk comparisonofgemcitabineplusnabpaclitaxelandfolfirinoxinmetastaticpancreaticcancer AT leenamkyung comparisonofgemcitabineplusnabpaclitaxelandfolfirinoxinmetastaticpancreaticcancer AT hongseungbaek comparisonofgemcitabineplusnabpaclitaxelandfolfirinoxinmetastaticpancreaticcancer AT seohyungil comparisonofgemcitabineplusnabpaclitaxelandfolfirinoxinmetastaticpancreaticcancer |